PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

No: 40 /PMC-HĐQT

Re: Explanation of the variance in business results for the second quarter of 2026 compared to the same period last year.

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Ho Chi Minh City, 17 July 2026

To:- STATE SECURITIES COMMISSION OF VIETNAM
- HANOI STOCK EXCHANGE

Pursuant to Circular No 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance on information disclosure on the securities market.

Based on the business performance in the second quarter of 2026 compared with the second quarter of 2025, Pharmedic Pharmaceutical Medicinal Joint Stock Company hereby explains the reasons for the fluctuation in business results exceeding 10% between the two reporting periods as follows:

In the second quarter of 2026, net revenue and total accounting profit before tax decreased by 9.97% and 39.86%, respectively, compared with the same period last year. This was mainly attributable to changes in the Company's sales policy, including higher trade discounts offered to customers. Meanwhile, the Company is investing in the replacement of aging production machinery and equipment and the renovation and expansion of its production facilities. As a result, depreciation expenses increased during the period, while interest income from term deposits declined significantly (down 89.25%), and interest expenses on short-term borrowings surged (up 3,597.98%).

We hereby certify that the information provided is true and accurate, and we assume full responsibility before the law for the content of this disclosure.

Recipients:
- As stated above;
- Archived.

LEGAL REPRESENTATIVE
GENERAL DIRECTOR

CÔNG TY CỔ PHẦN DƯỢC PHẨM DƯỢC LIỆU PHARMEDIC
M.S.D.N: 0300483037 - C.T.C.P
THÀNH PHỐ HỒ CHÍ MINH

LE VIET HUNG